At UCB we are driven by our commitment to people living with severe diseases who inspire our research and development across neurology, immunology, and other areas where our, expertise, innovation and ambition align with unmet needs. One such area of unmet need is in the management of thymidine kinase 2 deficiency (TK2d), where there are no approved therapies or international clinical guidelines. This rare, debilitating mitochondrial disorder affects children and adults, leading to progressive muscle weakness and severe mobility and respiratory challenges.
We’re proud to announce the publication of joint research on FLuID (Federated Learning Using Information Distillation) in Nature Machine Intelligence. This innovative approach has the potential to reshape how industries like pharmaceuticals collaborate while safeguarding sensitive data. A key challenge for AI in scientific research is accessing high-quality data for impactful models. Valuable knowledge often remains locked in confidential corporate data silos, despite industries being more open to sharing non-competitive insights. Federated learning allows knowledge sharing while preserving data privacy but has limitations...read more
At the AD/PD Congress, one of the leading global events for advancing science in Alzheimer’s and Parkinson’s diseases, we are reaffirming our commitment to tackling the challenges of these devastating neurodegenerative diseases. The conference provides an invaluable platform to connect with the scientific community, fuel dialogues that spark innovation, and drive progress in understanding the underlying mechanisms of these complex conditions.
As we prepare for the American Academy of Neurology (AAN) congress, we're excited to showcase UCB's dedication to transforming care for individuals living with neurological conditions. The AAN annual meeting isn't just an event; it's a gathering of the brightest minds in neurology, where breakthroughs are shared, and challenges are tackled head-on
UCB is proud to announce that our new carbon emissions reduction targets have been officially validated by the Science Based Targets initiative (SBTi), a significant achievement that underscores our commitment to sustainable impact and our dedication to reducing our environmental footprint. Specifically, our validated net-zero targets aim to reduce absolute scope 1, 2 and 3 greenhouse gas (GHG) emissions by 90% by 2045 (from our 2019 baseline), ensuring we are aligned with the latest climate science to meet the goals of the Paris Agreement and achieving net-zero before 2050. Learn more...
Recognized by the European Innovation scoreboard, Belgium has positioned itself as a powerhouse in healthcare and pharmaceutical innovation, with a unique blend of academic rigor and industry expertise driving its success. This thriving ecosystem is characterized by strong collaboration between leading research institutions and pharmaceutical companies, setting Belgium apart on a global level. The partnership between UCB and KU Leuven, a renowned research institution, is a prime example of the country's collaborative spirit. Learn more...
Meet Tracy: a Mom, Caregiver, Neuroscientist, and Advocate in the Rare Disease Community Each of us, throughout some stage in our life, will likely take on the role of a caregiver – of a child, a parent, or even a spouse or friend. Once we take that step, we are notorious for not taking care of ourselves in the same way we provide for others. In my own experience caring for a daughter living with a severe, life-threatening and rare form of epilepsy called Lennox-Gastaut syndrome (LGS), I am all too familiar with the mental burden that caregivers carry with them and the overall tendency to put our own needs last. Read more...
World Psoriasis Day 2024: Celebrating the invaluable role of family 29th October, marks World Psoriasis Day. For more than a decade, the global community has come together on this day to raise awareness and unite in their support of people living with psoriasis and psoriatic arthritis. Each year, the International Federation of Psoriasis Associations (IFPA) selects a theme for World Psoriasis Day. This year’s theme, ‘Psoriatic Disease and the Family’, aims to raise awareness of the impact living with psoriasis and psoriatic arthritis can have on both people living with these diseases and their family members. To mark World Psoriasis Day and this year’s theme, we had the honor of an insightful conversation with Caroline, who lives with psoriasis and psoriatic arthritis. Read more...
UCB at EADV 2024: committed to advancing care in immuno-dermatology As the European Academy of Dermatology and Venerology (EADV) annual congress approaches, UCB proudly reaffirms its commitment to advancing immuno-dermatology care. This prestigious event unites leading dermatologists, scientists, and healthcare professionals to share the latest research and address critical unmet needs. We are excited to explore how the scientific advancements showcased at this year’s congress in Amsterdam can enhance our ability to serve people living with dermatological diseases.
The American Society for Bone and Mineral Research (ASBMR) Annual Meeting is the largest and most comprehensive global congress dedicated to bone, mineral, and musculoskeletal health. Each year, thousands of leading experts, researchers, and clinicians from around the world gather to exchange knowledge and present the latest breakthroughs in disease management, treatment strategies, and scientific innovation. The 2024 meeting promises to continue this tradition of excellence, offering a unique platform for collaboration and discovery in the ever-evolving field of bone health. Read more...
